富含甘油三酯脂蛋白降低疗法的临床试验设计:JACC焦点研讨会3/3
富含甘油三酯脂蛋白(TRL)是动脉粥样硬化性心血管病患者的残余风险来源,与甘油三酯(TG)水平间接相关。既往降TG试验在辛伐他汀背景下未能减少主要不良心血管事件或未显示TG降低与事件减少的关联,试验设计局限可能解释此现象。随着RNA沉默疗法出现,本文讨论TRL病理生理、药物效应及心血管结局试验的最优设计。
要点
- TRL是ASCVD患者残余风险来源,与TG水平间接相关。
- 既往降TG试验在辛伐他汀背景下未显示事件减少或TG降低与事件关联。
- RNA沉默疗法背景下需优化心血管结局试验设计以评估TRL降低。
核心结论
- TRL是ASCVD患者残余风险来源,与TG水平间接相关,但既往降TG试验未能减少主要不良心血管事件或未显示TG降低与事件减少关联。
研究设计与样本
- 本文为JACC焦点研讨会,讨论TRL病理生理、TRL降低疗法的药理效应及心血管结局试验的最优设计。
主要发现
- 既往降TG试验在辛伐他汀背景下未能减少主要不良心血管事件或未显示TG降低与事件减少关联。
- 试验设计局限可能解释既往降TG疗法缺乏疗效。
- RNA沉默疗法靶向TG代谢通路,重新聚焦于降低TRL以减少主要不良心血管事件。
临床怎么用
- 心内科医生应关注TRL作为ASCVD残余风险,并理解既往降TG试验设计局限及RNA沉默疗法的新方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Triglyceride-rich lipoproteins (TRLs) are a source of residual risk in patients with atherosclerotic cardiovascular disease, and are indirectly correlated with triglyceride (TG) levels. Previous clinical trials studying TG-lowering therapies have either failed to reduce major adverse cardiovascular events or shown no linkage of TG reduction with event reduction, particularly when these agents were tested on a background of statin therapy. Limitations in trial design may explain this lack of efficacy. With the advent of new RNA-silencing therapies in the TG metabolism pathway, there is renewed focus on reducing TRLs for major adverse cardiovascular event reduction. In this context, the pathophysiology of TRLs, pharmacological effects of TRL-lowering therapies, and optimal design of cardiovascular outcomes trials are major considerations.
引用
- Malick WA, Waksman O, Do R, et al. Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies: JACC Focus Seminar 3/3. J Am Coll Cardiol. 2023. PMID: 37076219. doi:10.1016/j.jacc.2023.02.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。